Sign In
Buy CERE
$44.96
+0 (+0%)
At Close: Oct 30, 2024
Investors Of CERE Can Participate In The Probe Of Cerevel Therapeutics Holdings Inc Led By The Schall Law Firm
01:55pm, Wednesday, 19'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeut
CEREVEL STOCK INQUIRY: Is $45 Per Share Enough for Cerevel (CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price
03:41pm, Tuesday, 18'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you in
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
01:51pm, Tuesday, 18'th Jun 2024
LOS ANGELES--(BUSINESS WIRE)--CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm.
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you i
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you in
Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encou
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you in
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Thursday, 13'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you i
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you in
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Wednesday, 12'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you in
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Tuesday, 11'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) (“Cerevel”) on behalf of the company's shareholders. On Decembe
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you i
